Aro Biotherapeutics
Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins.
$41.5M Series B+ ·
Source: fundraisingfox.com
Funding history ↓Signals
X account@AroBioTx · created Oct 11, 2019 (7 years old) · 125 followers
Website registeredAug 11, 2017 (9 years old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | $41.5M | — | fundraisingfox.com |
Timeline
- X account created
- Website created
Founders and team
- KOKaryn O'Neil Co-founder and Chief Scientific Officersource: arobiotx.com
Companies like Aro Biotherapeutics
EEstuary Biotherapeutics$103M Series A · Oct 2026
RReCode TherapeuticsSeries B+ · Oct 2023SSplice Bio$140M Series B+ · Jun 2025
MMindpeak$15.3M Series A · Oct 2024
MManifold Bio$40M Series A · Jun 2022
NnChroma Bio$75M · Dec 2024
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/aro-biotherapeutics (get a free API key).